ESPR Esperion Therapeutics Inc

Price (delayed)

$7.79

Market cap

$220.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.06

Enterprise value

$515.69M

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make ...

Highlights
The quick ratio has grown by 31% from the previous quarter but it has contracted by 19% YoY
Esperion Therapeutics's debt has surged by 198% YoY and by 12% QoQ
The net income has plunged by 108% from the previous quarter

Key stats

What are the main financial stats of ESPR
Market
Shares outstanding
28.28M
Market cap
$220.28M
Enterprise value
$515.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.3
Earnings
Revenue
$62.11M
EBIT
-$291.39M
EBITDA
-$290.76M
Free cash flow
-$292.25M
Per share
EPS
-$12.06
Free cash flow per share
-$11.14
Book value per share
-$10.79
Revenue per share
$2.37
TBVPS
$10.69
Balance sheet
Total assets
$280.46M
Total liabilities
$584.77M
Debt
$514.6M
Equity
-$304.31M
Working capital
$192.53M
Liquidity
Debt to equity
-1.69
Current ratio
3.33
Quick ratio
2.92
Net debt/EBITDA
-1.02
Margins
EBITDA margin
-468.2%
Gross margin
91.1%
Net margin
-522.5%
Operating margin
-469.3%
Efficiency
Return on assets
-111.6%
Return on equity
N/A
Return on invested capital
-85.3%
Return on capital employed
-147.3%
Return on sales
-469.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
-11.38%
1 week
-12.08%
1 month
-32.73%
1 year
-75.89%
YTD
-70.04%
QTD
-35.35%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$62.11M
Gross profit
$56.56M
Operating income
-$291.48M
Net income
-$324.52M
Gross margin
91.1%
Net margin
-522.5%
The company's operating income has shrunk by 125% QoQ
The net income has plunged by 108% from the previous quarter
The company's gross profit has shrunk by 75% QoQ and by 74% YoY
ESPR's revenue has dropped by 73% since the previous quarter and by 71% year-on-year

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.3
Esperion Therapeutics's EPS has shrunk by 105% QoQ
The equity has decreased by 13% QoQ
ESPR's revenue has dropped by 73% since the previous quarter and by 71% year-on-year
The price to sales (P/S) is 34% lower than the last 4 quarters average of 5.0

Efficiency

How efficient is Esperion Therapeutics business performance
The return on assets has dropped by 117% since the previous quarter
The return on invested capital has dropped by 63% since the previous quarter and by 51% year-on-year

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 52% less than the total liabilities
ESPR's total liabilities has surged by 139% year-on-year and by 7% since the previous quarter
The quick ratio has grown by 31% from the previous quarter but it has contracted by 19% YoY
Esperion Therapeutics's debt has surged by 198% YoY and by 12% QoQ
ESPR's debt to equity has dropped by 184% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.